Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -0.12
- Piotroski Score 3.00
- Grade Buy
- Symbol (TNGX)
- Company Tango Therapeutics, Inc.
- Price $3.60
- Changes Percentage (-6.62%)
- Change -$0.26
- Day Low $3.54
- Day High $3.83
- Year High $13.01
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/17/2025
- Fiscal Year End N/A
- Average Stock Price Target $13.00
- High Stock Price Target $18.00
- Low Stock Price Target $13.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.11
- Trailing P/E Ratio -6.22
- Forward P/E Ratio -6.22
- P/E Growth -6.22
- Net Income $-101,744,000
Income Statement
Quarterly
Annual
Latest News of TNGX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Tango Therapeutics, Inc. (TNGX) Stock Price, News, Quote & History - Yahoo Finance
Tango Therapeutics, a biotech company, focuses on developing cancer drugs like TNG908 and TNG462 for specific cancer types. They collaborate with Gilead Sciences to discover and commercialize therapie...
By Yahoo! Finance | 4 months ago
